BioCryst receives $44 million federal agency to help develop galidesivir. | Stock Photo
BioCryst receives $44 million federal agency to help develop galidesivir. | Stock Photo
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded BioCryst Pharmaceuticals, Inc. with a new $44 million contract, BioCryst said in a company release.
NIAID also included $3 million into the current contract it has with BioCryst to help fund the galidesivir production.
“With this additional investment in galidesivir by NIAID, we are now positioned to further evaluate and advance galidesivir through additional clinical trials in different settings beyond hospitalized patients, and to accelerate our manufacturing activities to increase drug supply,” Jon Stonehouse, chief executive officer of BioCryst, said in the company release on Aug. 31. “We appreciate the financial investment the government continues to make in the galidesivir program. We believe broad-spectrum antivirals, like galidesivir, are critical to combat both the current COVID-19 pandemic and threats from future viruses.”
The extra money in the contracts will help back several aspects of the project like boosting the amount of galidesivir and hosting a second phase of the clinical trial of galidesivir in COVID-19 patients who aren’t at the hospital but are at high risk of experiencing complications.
Alerts Sign-up